Cosentyx SensoReady® 150mg pen self injection video
Cosentyx UnoReady® 300mg pen self injection video
Rate this content:
IE271483 | March 2023
Reporting of side effects
Reporting suspected adverse reactions of the medicinal product is important to Novartis and the HPRA. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported via HPRA Pharmacovigilance, website: www.hpra.ie. Adverse events could also be reported to Novartis preferably via www.report.novartis.com or by email: [email protected] or by calling 01 2080 612.
×
Ask Speakers
×